Metüülfenidaat

Metüülfenidaat (kaubanimega Ritalin, Concerta jt) on kesknärvisüsteemi stimulant (fenüülalküülamiin), mida kasutatakse peamiselt aktiivsus- ja tähelepanuhäire (ATH) raviks. Harvem on sellega ravitud ka narkolepsiat.

ATH ravil on selle efektiivsust hinnatud võrdseks atomoksetiiniga^[1]^[2]^[3]^[4] ja veidi väiksemaks võrreldes amfetamiiniga^[5]^[6]^[7]^[8].

Üksikutel juhtudel võib ravimi kasutajatel välja kujuneda ravimisõltuvus, see oht on aga tunduvalt väiksem kui amfetamiini puhul.

Eestis kasutatakse seda tänapäeval ainult aktiivsus- ja tähelepanuhäire korral, kuid varem on kasutatud ka apatiko-abuulilise sündroomiga haigete aktiveerimiseks või muu asteenia või loiduse korral.

Viited

↑ Bushe C, Day K, Reed V, Karlsdotter K, Berggren L, Pitcher A, Televantou F, Haynes V (mai 2016). "A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients". Journal of Psychopharmacology. 30 (5): 444–458. DOI:10.1177/0269881116636105. PMID 27005307. S2CID 104938.
↑ Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW (november 2011). "Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis". Journal of Attention Disorders. 15 (8): 674–683. DOI:10.1177/1087054710379737. PMID 20837981. S2CID 43503227.
↑ Hanwella R, Senanayake M, de Silva V (november 2011). "Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis". BMC Psychiatry. 11 (1): 176. DOI:10.1186/1471-244X-11-176. PMC 3229459. PMID 22074258.
↑ Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, Bidaki R, Nouri B (10. veebruar 2016). "Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis". Medical Journal of the Islamic Republic of Iran. 30: 325. PMC 4898838. PMID 27390695.
↑ Stuhec M, Lukić P, Locatelli I (veebruar 2019). "Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis". The Annals of Pharmacotherapy. 53 (2): 121–133. DOI:10.1177/1060028018795703. PMID 30117329. S2CID 52019992.
↑ Faraone SV, Pliszka SR, Olvera RL, Skolnik R, Biederman J (juuni 2001). "Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology". Journal of Child and Adolescent Psychopharmacology. 11 (2): 171–180. DOI:10.1089/104454601750284081. PMID 11436957. Mall:ProQuest.
↑ Faraone SV, Biederman J, Roe C (oktoober 2002). "Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis". Journal of Clinical Psychopharmacology. 22 (5): 468–473. DOI:10.1097/00004714-200210000-00005. PMID 12352269. S2CID 19726926.
↑ Faraone SV, Buitelaar J (aprill 2010). "Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis". European Child & Adolescent Psychiatry. 19 (4): 353–364. DOI:10.1007/s00787-009-0054-3. PMID 19763664. S2CID 9447892.

Allikad

Lembit Allikmets, Lembit Mehilane, Jüri Saarma, Märt Saarma ja Vaino Vahing "Kliiniline psühhofarmakoloogia", Valgus 1981, lk. 138-139.

[:33-1] Bushe C, Day K, Reed V, Karlsdotter K, Berggren L, Pitcher A, Televantou F, Haynes V (mai 2016). "A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients". Journal of Psychopharmacology. 30 (5): 444–458. DOI:10.1177/0269881116636105. PMID 27005307. S2CID 104938.

[:22-2] Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW (november 2011). "Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis". Journal of Attention Disorders. 15 (8): 674–683. DOI:10.1177/1087054710379737. PMID 20837981. S2CID 43503227.

[:03-3] Hanwella R, Senanayake M, de Silva V (november 2011). "Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis". BMC Psychiatry. 11 (1): 176. DOI:10.1186/1471-244X-11-176. PMC 3229459. PMID 22074258.

[:13-4] Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, Bidaki R, Nouri B (10. veebruar 2016). "Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis". Medical Journal of the Islamic Republic of Iran. 30: 325. PMC 4898838. PMID 27390695.

[5] Stuhec M, Lukić P, Locatelli I (veebruar 2019). "Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis". The Annals of Pharmacotherapy. 53 (2): 121–133. DOI:10.1177/1060028018795703. PMID 30117329. S2CID 52019992.

[6] Faraone SV, Pliszka SR, Olvera RL, Skolnik R, Biederman J (juuni 2001). "Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology". Journal of Child and Adolescent Psychopharmacology. 11 (2): 171–180. DOI:10.1089/104454601750284081. PMID 11436957. Mall:ProQuest.

[7] Faraone SV, Biederman J, Roe C (oktoober 2002). "Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis". Journal of Clinical Psychopharmacology. 22 (5): 468–473. DOI:10.1097/00004714-200210000-00005. PMID 12352269. S2CID 19726926.

[8] Faraone SV, Buitelaar J (aprill 2010). "Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis". European Child & Adolescent Psychiatry. 19 (4): 353–364. DOI:10.1007/s00787-009-0054-3. PMID 19763664. S2CID 9447892.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]